On Monday, Barclays (LON:BARC) made a decisive move by downgrading Definitive Healthcare Corp (NASDAQ:DH)'s stock rating from Equal Weight to Underweight, while maintaining a price target of $4.00. This adjustment reflects concerns over the company's revenue trajectory and competitive challenges. According to InvestingPro data, the company maintains a "GOOD" overall financial health score, with a strong current ratio of 2.49 indicating solid liquidity.
Definitive Healthcare, traded on the NASDAQ under the ticker DH, has been flagged by Barclays for a trio of troubling signs. Firstly, the company is expected to see declining revenue in fiscal year 2025, a trend not common among the firm's software coverage. This decline is attributed to an increased churn of life sciences customers, which has shown no signs of improvement. InvestingPro analysis suggests the stock is currently undervalued, trading at a price-to-book ratio of 1.29 and an EV/EBITDA multiple of 18.94.
Secondly, Definitive Healthcare is undergoing sales force changes aimed at addressing the falling customer count and weaker renewals. However, Barclays cautions that these alterations will require time to take effect and are likely to negatively impact profit margins in the short term. Despite these challenges, InvestingPro data reveals that net income is expected to grow this year, with analysts predicting profitability. Discover 5 more exclusive InvestingPro Tips and comprehensive analysis in our Pro Research Report.
Lastly, while there is a possibility that the macroeconomic environment could improve or that the sales force changes might lead to a quicker pipeline build, potentially setting the stage for a turnaround, Barclays remains cautious.
The firm also raises concerns about the increasing competition in the commercial healthcare data space, particularly from Veeva's Data Cloud product, which presents an additional threat to Definitive Healthcare's market position. The stock has seen a significant decline, with a one-year total return of -55.15%, though it has shown some resilience with a 2.68% gain year-to-date.
Barclays' analyst Saket Kalia's statement underlines the rationale behind the downgrade, emphasizing the challenges faced by Definitive Healthcare and the factors that could influence its future performance. Despite these concerns, the price target for Definitive Healthcare's stock remains set at $4.00.
In other recent news, Definitive Healthcare, a prominent player in healthcare data and analytics, reported mixed third-quarter earnings results. Despite a slight year-over-year decline in revenue and adjusted EBITDA, the company exceeded its revenue guidance with a total revenue of $62.7 million and maintained a stable adjusted EBITDA margin of 33%. The company also announced an expansion of its share buyback program by $100 million, demonstrating confidence in its long-term prospects.
However, Definitive Healthcare is facing challenges with customer churn, particularly in the life sciences sector, and anticipates revenue volatility into early 2025. In response, the company is focusing on strategic initiatives to enhance customer retention and operational efficiency.
Furthermore, the company's CFO, Rick Booth, announced his departure effective June 1, 2025. As these developments unfold, Definitive Healthcare remains active in mergers and acquisitions, with sufficient capital for potential deals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.